PharmaIN is at the forefront of developing innovative peptide-based therapeutics aimed at addressing significant unmet medical needs in niche patient populations, particularly in the fields of liver disease and oncology. Their lead investigational drug, PHIN-214, is currently undergoing a Phase 1b clinical trial targeting refractory ascites, a severe complication of liver cirrhosis. This drug aims to disrupt the renin-angiotensin-aldosterone system (RAAS) signaling pathway, which is responsible for the retention of excess salt and water, thereby potentially providing a new pharmacological approach to managing this condition. Additionally, PharmaIN is advancing PHIN-1314, a first-in-class tumor microenvironment modifier designed to treat various solid tumors, either alone or in combination with existing immuno-oncology therapies.

The company’s research is underpinned by a robust intellectual property portfolio, encompassing over 20 families of patents that protect their scientific advancements. Their focus on liver cirrhosis is particularly relevant given the rising incidence of conditions like non-alcoholic steatohepatitis (NASH), which is linked to obesity and diabetes. By targeting specific receptors involved in cancer progression, PharmaIN aims to leverage their unique mechanisms of action to develop effective treatments for solid tumors, with ongoing studies to further explore the efficacy and safety of their drug candidates.

United States

PharmaIN Corporation is a company dedicated to developing proprietary peptide drugs for in-home treatment of liver disease and cancer. PHIN-214 is an investigational drug therapy that has not been approved by the FDA or any other regulatory agency.

PharmaIN

Company Details